LB54640
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Rhythm · Phase 2 · Completed · Enrollment 28
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Bivamelagon Low dose (200 milligrams [mg]) | Obesity or overweight | n/r | 14 | n/r | n/r |
| Bivamelagon Middle dose (400 mg) | Obesity or overweight | 400 mg | 14 | n/r | n/r |
| Bivamelagon High dose (600 mg) | Obesity or overweight | 600 mg | 14 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 14 | n/r | n/r |
| Open-label Bivamelagon | Obesity or overweight | n/r | 14 | n/r | n/r |